14 results on '"Nair N."'
Search Results
2. Paradigm shift in surgery for breast cancer: The Indian reality
- Author
-
Nair, N.
- Subjects
Lumpectomy -- Usage -- Statistics -- Forecasts and trends ,Breast cancer -- Care and treatment -- Demographic aspects -- Forecasts and trends ,Market trend/market analysis ,Health - Abstract
Byline: N. Nair The latter part of the last millennium was a period of new discoveries in science and medicine, with a new understanding of the cause and treatment of [...]
- Published
- 2011
3. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma
- Author
-
Tiwari, B., Jangra, S., Nair, N., Tongaonkar, H., and Basu, S.
- Subjects
Prostate cancer -- Diagnosis -- Care and treatment -- Research ,Metastasis -- Diagnosis -- Research ,PET imaging -- Usage -- Health aspects ,Bone densitometry -- Usage ,Health - Abstract
Byline: B. Tiwari, S. Jangra, N. Nair, H. Tongaonkar, S. Basu Prostate cancer is one of the most common malignancies of elderly males. Management depends on the accurate estimation of [...]
- Published
- 2010
4. Squamous cell carcinoma of esophagus masquerading as solitary thyroid nodule
- Author
-
Basu, S., Nair, N., and Borges, A.
- Subjects
Squamous cell carcinoma -- Care and treatment ,Thyroid diseases -- Care and treatment - Abstract
Byline: S. Basu, N. Nair, A. Borges Secondary neoplasm of the thyroid mimicking a primary thyroid lesion is a rare finding, especially in an individual without a past history of [...]
- Published
- 2005
5. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India
- Author
-
Gupta, S, primary, Shet, T, additional, Suryavanshi, P, additional, Jalali, R, additional, Hawaldar, R, additional, Nair, N, additional, Ghosh, J, additional, Desai, S, additional, Radhakrishnan, S, additional, Parmar, V, additional, Goyal, G, additional, Patil, A, additional, and Badwe, RA, additional
- Published
- 2011
- Full Text
- View/download PDF
6. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma
- Author
-
Basu, S, primary, Tiwari, BP, additional, Jangra, S, additional, Nair, N, additional, and Tongaonkar, HB, additional
- Published
- 2010
- Full Text
- View/download PDF
7. Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience.
- Author
-
Joshi S, Chougle Q, Noronha J, Hawaldar R, Nair N, Vanmali V, Parmar V, Thakkar P, Chitkara G, Shet T, and Badwe RA
- Subjects
- Humans, Female, Middle Aged, Adult, Aged, Receptor, ErbB-2 metabolism, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy methods, Breast Neoplasms drug therapy, Breast Neoplasms pathology
- Abstract
Background: Neoadjuvant chemotherapy (NACT) is routinely used in all cases of locally advanced breast cancer and some cases of early breast cancer. We previously reported a pathological complete response (pCR) rate of 8.3%. With the increasing use of taxanes and human epidermal growth factor receptor 2 (HER2)-directed NACT, we conducted this study to understand the current pCR rate and its determinants., Methods: A prospective database of breast cancer patients who underwent NACT followed by surgery between January and December 2017 was evaluated., Results: Of the 664 patients, 87.7% were cT3/T4, 91.6% were grade III, and 89.8% were node-positive at presentation (54.4% cN1, 35.4% cN2). The median age was 47 years; median pre-NACT clinical tumor size was 5.5 cm. Molecular subclassification was 30.3% hormone receptor positive (HR+) HER2-, 18.4% HR+HER2+, 14.9% HR-HER2+, and 31.6% triple negative (TN). Both anthracyclines and taxanes were given preoperatively in 31.2% patients whereas 58.5% of HER2 positive patients received HER2-targeted NACT. The overall pCR rate was 22.4% (149/664), 9.3% in HR+HER2-, 15.6% in HR+HER2+, 35.4% in HR-HER2+, and 33.4% in TN. On univariate analysis, duration of NACT ( P < 0.001), cN stage at presentation ( P = 0.022), HR status ( P < 0.001), and lymphovascular invasion ( P < 0.001) were associated with pCR. On logistic regression, HR negative status (Odds ratio [OR] 3.314, P < 0.001), longer duration of NACT (OR 2.332, P < 0.001), cN2 stage (OR 0.57, P = 0.012), and HER2 negativity (OR 1.583, P = 0.034) were significantly associated with pCR., Conclusion: Response to chemotherapy depends on molecular subtype and duration of NACT. A low rate of pCR in the HR+ subgroup of patients warrants reconsideration of neoadjuvant strategies., (Copyright © 2024 Copyright: © 2024 Indian Journal of Cancer.)
- Published
- 2024
- Full Text
- View/download PDF
8. Post mastectomy pain syndrome at an Indian tertiary cancer centre and its impact on quality of life.
- Author
-
Kakati B, Nair N, and Chatterjee A
- Subjects
- Humans, Female, Mastectomy adverse effects, Pain, Postoperative etiology, Axilla, Quality of Life, Breast Neoplasms epidemiology, Breast Neoplasms surgery, Breast Neoplasms complications
- Abstract
Background: Literature on Post mastectomy pain in the Indian population is scarce. Most literature is from the West. The current study aimed to identify the incidence of post-mastectomy pain syndrome (PMPS), pain severity, and its impact on quality of life in Indian patients., Method: Prospective observational study of 120 women undergoing mastectomy between March and December 2017, followed until 6 months after surgery. The Brief Pain Inventory (BPI) questionnaire and the quality of life questionnaire (QLQ) by the European Organization for Research and Treatment of Cancer (EORTC) and known as (EORTC-QLQ 30) were used to identify the impact on function and quality of life., Results: A 35.8% PMPS incidence was identified at 6 months after mastectomy. Pain was located in the anterior chest wall (41.8%), axilla (32.6%), and medial upper arm (25.6%). Most (48.8%) patients described it as dull aching and of mild intensity (55.8%). No significant association of age, BMI, surgery, Intercostobrachial nerve (ICBN) dissection, postoperative pain severity, pain history {dysmenorrhea, headache}, and postoperative radiotherapy with PMPS was found. Pain interfered with daily activities and quality of life in those with PMPS, as deduced from BPI and EORTC-QLQ., Conclusion: PMPS is very much a problem affecting the quality of life in our set of patients. Most women tried to cope and accept the pain as part of the treatment process. This shows the need for creating awareness about PMPS among healthcare providers and patients alike. Early identification and treatment of post mastectomy pain should be an essential aspect of patient care.
- Published
- 2023
- Full Text
- View/download PDF
9. Retrospective audit of the yield of internal mammary lymph node dissection and literature review in the management of breast cancer.
- Author
-
Joshi S, Chigurupati P, Reddy A, Noronha J, Hawaldar R, Nair N, Parmar V, Chitkara G, Thakkar P, Shet T, and A BR
- Abstract
Background: Treatment of lymph node basins is prognostic and therapeutic for axillary lymph nodes (ALN) as well as internal mammary lymph nodes (IMLNs) in breast cancer. IMLNs can be the first echelon node for the inner/central quadrants of the breast. We evaluated the yield of IMLN dissection (IMLND) mainly in patients with inner and central tumors., Methods: IMLND was performed in 199 patients between 2000 and 2018, 127 of whom had tumors in the inner/ central quadrants. Clinico-pathological data were retrieved from Electronic Medical Records (EMR)., Results: The median age was 50 (range: 24-81). Primary surgery was performed in 82 (41.2%), while 117 (58.8%) were operated post-chemotherapy. Overall, 124/199 (62.3%) had nodes identified in the specimen, more often in primary (61/82, 74.4%) than post-chemotherapy settings (63/117, 53.8%) (P = 0.003). A median of 1 (average: 1.24, range: 0-7) lymph nodes was dissected, and 1 (average: 1.5, range: 1-4) was involved. IMLN was positive in 46/199 (23.1%) patients, not significantly different in primary (21/82, 25.6%) versus post-chemotherapy (25/117, 21.4%) settings (P = 0.545). IMLN was involved in 44.8% of patients with ≥4 involved ALN and 8.2% with uninvolved ALN (P < 0.001). In the absence of ALN involvement and <2cm pT size, 9% of patients had positive IMLN in inner/central quadrant tumors. In univariate analysis, ALN positivity (P < 0.001), pT size (P = 0.023), and grade (P = 0.041) in primary and ALN involvement (P = 0.011) in post-chemotherapy patients were associated with IMLN involvement. On logistic regression, tumor size (OR: 13.914, P = 0.017) and ALN involvement (OR: 11.400, P = 0.005) in primary surgery and ALN involvement (OR: 7.294, P = 0.003) in post-chemotherapy patients correlated with IMLN involvement., Conclusions: In inner/central quadrant tumors, IMLN is more likely involved with high ALN burden and tumor size >2 cm, whereas those with ≤2cm inner/central quadrant tumors and negative ALN have <10% probability of IMLN involvement., (Copyright © 2023 Copyright: © 2023 Indian Journal of Cancer.)
- Published
- 2023
- Full Text
- View/download PDF
10. Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer.
- Author
-
Ghosh J, Joy Phillip DS, Ghosh J, Bajpai J, Gulia S, Parmar V, Nair N, Joshi S, Sarin R, Budrukkar AN, Wadasadawala T, Desai SB, Shet T, Patil A, Sawant SP, Dhir AA, Kembhavi S, Popat P, Hawaldar R, Kembhavi Y, Perumal P, Banavali SD, Badwe RA, and Gupta S
- Subjects
- Female, Humans, Middle Aged, Anthracyclines therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Disease-Free Survival, Paclitaxel therapeutic use, Receptor, ErbB-2 metabolism, Retrospective Studies, Trastuzumab therapeutic use, Breast Neoplasms pathology, Neoadjuvant Therapy adverse effects
- Abstract
Background: There is limited access to 1 year of adjuvant trastuzumab in resource-constrained settings. Most randomized studies have failed to prove non-inferiority of shorter durations of adjuvant trastuzumab compared to 1 year However, shorter durations are often used when 1 year is not financially viable. We report the outcomes with 12 weeks of trastuzumab administered as part of curative-intent treatment., Methods: This is a retrospective analysis of patients treated at Tata Memorial Centre, Mumbai, a tertiary care cancer center in India. Patients with human epidermal growth factor receptor (HER2)-positive early or locally advanced breast cancer who received 12 weeks of adjuvant or neoadjuvant trastuzumab with paclitaxel and four cycles of an anthracycline-based regimen in either sequence, through a patient assistance program between January 2011 and December 2012, were analyzed for disease-free survival (DFS), overall survival (OS), and toxicity., Results: A total of 102 patients were analyzed with a data cutoff in September 2019. The median follow-up was 72 months (range 6-90 months), the median age was 46 (24-65) years, 51 (50%) were postmenopausal, 37 (36%) were hormone receptor-positive, and 61 (60%) had stage-III disease. There were 37 DFS events and 26 had OS events. The 5-year DFS was 66% (95% Confidence Interval [CI] 56-75%) and the OS was 76% (95% CI 67-85%), respectively. Cardiac dysfunction developed in 11 (10.7%) patients., Conclusion: The use of neoadjuvant or adjuvant 12-week trastuzumab-paclitaxel in sequence with four anthracycline-based regimens resulted in acceptable long-term outcomes in a group of patients, most of whom had advanced-stage nonmetastatic breast cancer., Competing Interests: None
- Published
- 2022
- Full Text
- View/download PDF
11. Grossing and reporting of breast cancer specimens: An evidence-based approach.
- Author
-
Shet T, Pai T, Wadasadawala T, Nair N, and Gulia S
- Subjects
- Female, Humans, Breast Neoplasms epidemiology, Disease Notification methods, Evidence-Based Medicine methods
- Abstract
A histopathology report offers important prognostic and predictive information that helps plan systemic therapy in breast cancer. However, in many cases a pathologist fails to provide relevant information chiefly due to the lack of awareness of the impact of these parameters in clinical decision-making. This review seeks to put forth common practice points in grossing and reporting of specimens harboring breast cancer with focus on latest revisions in the same. Just as it is important to document tumor size, tumor type, margins, estrogen receptor/progesterone receptor, and human epidermal growth factor (ER/PR/HER2) in breast cancer, we need to also focus on sentinel node grossing, nodal burden, size of nodal metastasis, and extranodal extension. In parallel, increasing number of patients are getting neoadjuvant chemotherapy in breast cancer and points in grossing and reporting of such specimens are also alluded to. This article will serve as reference guide to pathologists on what we do and why we do the same., Competing Interests: None
- Published
- 2020
- Full Text
- View/download PDF
12. Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis.
- Author
-
Nair N, Shet T, Parmar V, Havaldar R, Gupta S, Budrukkar A, Sarin R, Thakur M, Desai S, Yadav P, Jalali R, Gulia S, Wadasadawala T, Gosh J, Bajpai J, Kembhavi S, Patil A, Joshi S, Popat P, Rangarajan V, Shah S, Vanmali V, Siddiqui S, Mittra I, and Badwe R
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms genetics, Breast Neoplasms pathology, Breast Neoplasms surgery, Disease-Free Survival, Female, Gene Expression Regulation, Neoplastic, Humans, Mastectomy, Middle Aged, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Tertiary Care Centers, Treatment Outcome, Young Adult, Breast Neoplasms epidemiology, Neoplasm Recurrence, Local epidemiology, Receptor, ErbB-2 genetics
- Abstract
Background: Survival studies may serve as benchmarks to develop cancer-related policies and estimate baseline survival rates in a given patient population., Materials and Methods: We carried out a retrospective audit of cases managed in 2009 and now report the disease-free survival (DFS) in early breast cancer (EBC) and locally advanced breast cancer (LABC) in patients registered at a tertiary cancer center in India., Results: The study included 2192 patients with breast cancer with ages ranging from 18 years to 94 years with a median of 50 years. Of these, 888 (40.5%) were EBCs Stage I and II, 833 (38%) were LABCs (Stage III), and 471 (21.5%) were de novo metastatic or relapsed cancers at presentation. The 5-year DFS in the women with EBC was 85.5% and in LABC, it was 67.7%, P < 0.001. The factors adversely affecting DFS in EBC were node metastasis (P < 0.001), higher metastatic nodes (P < 0.001), hormone receptor negativity (P = 0.001), and human epidermal growth factor receptor 2 (Her2neu) positivity (P = 0.033). In the multivariate Cox regression analysis in EBC, node-positive status (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.51-3.45, P < 0.001) and hormone receptor negative tumors (HR 1.96, 95% CI 1.30-2.94, P = 0.001) significantly affected DFS in EBC. The factors adversely affecting DFS in LABC in the univariate analysis were node metastasis (P < 0.001), increasing numbers of nodes (P < 0.001), presence of lymphovascular emboli (LVE) (P < 0.01), mastectomy (P < 0.001), and Her2neu positivity (P = 0.03). In the multivariate Cox regression analysis, node positivity (HR 2.96, 95% CI 2.04-4.29, P < 0.0001), presence of LVE (HR 1.47, 95% CI 1.06-2.04, P = 0.023), and mastectomy (HR 1.49, 95% CI 1.06-2.10, P = 0.023) adversely impacted DFS in LABC., Conclusions: The survival rates in this study are equal to the documented global rates; nodal disease burden emerged as the most important prognostic factor. In addition, in EBCs, a lack of hormone receptor expression and in LABC, Her2neu overexpression appear to worsen the outcome., Competing Interests: There are no conflicts of interest
- Published
- 2018
- Full Text
- View/download PDF
13. (18)FDG PET in primary oat cell carcinoma of the esophagus.
- Author
-
Basu S and Nair N
- Subjects
- Aged, Carcinoma, Small Cell complications, Carcinoma, Small Cell diagnostic imaging, Carcinoma, Small Cell pathology, Deglutition Disorders etiology, Diagnosis, Differential, Esophageal Neoplasms complications, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms pathology, Female, Fluorodeoxyglucose F18, Humans, Middle Aged, Positron-Emission Tomography, Radiopharmaceuticals, Carcinoma, Small Cell diagnosis, Esophageal Neoplasms diagnosis
- Abstract
The role of FDG-PET in oat cell carcinoma of the esophagus is hitherto unexplored. A MEDLINE search using the terms "small cell carcinoma" or "oat cell carcinoma" combined with "FDG-PET" yielded no report on this issue till date. We report, in this article, two cases depicting the usefulness of this modality in the management of this uncommon neoplasm. While reevaluation of unsuspected metastatic sites missed by other modalities suggest its role in M staging, whole body FDG PET (both baseline as well as post treatment) may find important role in treatment monitoring and evaluation in residual viable disease, taking into account the systemic nature of the disease.
- Published
- 2005
- Full Text
- View/download PDF
14. Identification of risk factors for specific subsites within the oral and oropharyngeal region--a study of 647 cancer patients.
- Author
-
Dhar PK, Rao TR, Sreekumaran Nair N, Mohan S, Chandra S, Bhat KR, and Rao K
- Subjects
- Adult, Aged, Blood Group Antigens, Female, Humans, Male, Middle Aged, Mouth Floor pathology, Mouth Mucosa pathology, Mouth Neoplasms epidemiology, Oropharyngeal Neoplasms epidemiology, Risk Factors, Tongue Neoplasms epidemiology, Alcohol Drinking adverse effects, Mouth Neoplasms etiology, Oropharyngeal Neoplasms etiology, Smoking adverse effects, Nicotiana adverse effects, Tongue Neoplasms etiology
- Abstract
Studies on site specific risks for oral cancers are few. Present investigation explores the possible role of human sociodemographic factors in causing oral cancer. Majority of patients had poor oral hygiene (85.5%) and belonged to 51-60 years age group (35.7%). Most of the subjects were agriculture workers (30.3%). Tongue and floor of mouth included majority of the affected sites (77.2%). Male to female ratio was highest for tonsil (32.3%) but differed marginally for other subsites. Majority of females used tobacco (81%) while males users of tobacco, alcohol and smoking reported in nearly equal proportions. Tobacco and smoking were found as primary risk factors for several intraoral subsites. However, for tongue, palate and lip no risk factor could be identified from given patients' characteristics. In general, tobacco posed high risk for buccal mucosa and alveolus in comparison to other subsites. Smoking affected tonsil and floor of mouth more than other sites. Alcohol posed more risk for buccal mucosa and floor of mouth than tongue.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.